B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PDE4B

MOLECULAR TARGET

phosphodiesterase 4B

UniProt: Q07343NCBI Gene: 514222 compounds

PDE4B (phosphodiesterase 4B) is targeted by 22 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PDE4B

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1rolipram5.12166
2sildenafil4.78118
3roflumilast4.0456
4isobutylmethylxanthine3.7140
5cilomilast3.7140
6piclamilast3.0420
7apremilast2.8917
8 rolipram2.8316
9zardaverine2.7715
10crisaborole2.7114
11cdp8402.7114
12moracin m2.5612
13ro 2017242.5612
14ibudilast2.4811
15moracin c2.4010
16gsk7782.087
17phthalazinone1.795
18arctigenin-4-O-(3''-O-acetyl-beta-D-glucoside) [Supplementary Concept] isolated from0.691
19Etazolate0.691
20Muscarine0.691
21Papaverine0.691
22bdb chembl47487500.691

About PDE4B as a Drug Target

PDE4B (phosphodiesterase 4B) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 22 compounds with documented PDE4B interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PDE4B inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.